促红细胞生成素衍生物研究进展  

Research Progress of Carbamylated Erythropoietin

作　　者：马宝新[1] 刘现亮[1] 

机构地区：[1]滨州医学院附属医院,山东滨州256603

出　　处：《心血管病学进展》2011年第2期288-291,共4页Advances in Cardiovascular Diseases

摘　　要：促红细胞生成素(EPO)除了具有造血活性外,还具有抗凋亡等广泛的组织保护活性。近年来的研究发现促红细胞生成素衍生物———氨甲酰化促红细胞生成素(CEPO),不表现任何促红细胞生成活性,不能与经典促红细胞生成素受体(EPOR)结合,但可通过新发现的一种受体EPOR-βcR(由EPOR和βcR形成的异源二聚体)起到与EPO类似的组织保护作用。与EPO不同,CEPO无明显的造血活性,CEPO的抗凋亡保护作用与其改善组织重塑及抑制瘢痕形成有关。Erythropoietin（EPO）,a hematopoietic cytokine,possesses strong antiapoptotic tissue-protective properties.Recently several studies have shown that carbamylated EPO（CEPO） did not bind to the classical EPO receptor（EPOR） and did not show any hematopoietic activity.Nevertheless,CEPO showed tissue protection through its ability to bind to a new hetero-receptor complex comprising both EPOR and common β receptor（βcR） at a potency and efficacy comparable to EPO.Unlike EPO,CEPO has no effect on hematocrit.CEPO showed the antiapoptotic protective effects through its ability to limit both remodeling and the extent of the scar.

关 键 词：促红细胞生成素 氨甲酰促红细胞生成素 促红细胞生成素受体 βcR 器官保护作用 

分 类 号：R692.5[医药卫生—泌尿科学]